Climb Bio, Inc.
General ticker "CLYM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $282.9M (TTM average)
Climb Bio, Inc. follows the US Stock Market performance with the rate: 55.6%.
Estimated limits based on current volatility of 3.4%: low 12.71$, high 13.62$
Factors to consider:
- Total employees count: 29 (+61.1%) as of 2025
- Top business risk factors: Need for additional capital, Clinical trial failure, Regulatory and compliance, Manufacturing risks, Market competition
- Current price 124.2% above estimated high
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.32$, 5.93$]
- 2026-12-31 to 2027-12-31 estimated range: [1.59$, 4.26$]
Short-term CLYM quotes
Long-term CLYM plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $40.27MM | $82.02MM | $67.88MM |
| Operating Income | $-40.27MM | $-82.02MM | $-67.88MM |
| Non-Operating Income | $5.51MM | $8.15MM | $8.44MM |
| R&D Expense | $15.41MM | $66.00MM | $46.71MM |
| Income(Loss) | $-34.76MM | $-73.87MM | $-59.44MM |
| Net Income(Loss)* | $-35.12MM | $-73.90MM | $-59.85MM |
| Stockholders Equity | $107.60MM | $211.88MM | $160.47MM |
| Assets | $110.47MM | $217.19MM | $167.74MM |
| Operating Cash Flow | $-20.60MM | $-15.56MM | $-54.36MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.19MM |
| Investing Cash Flow | $68.98MM | $-121.09MM | $2.83MM |
| Financing Cash Flow | $0.84MM | $130.73MM | $-0.02MM |
| Earnings Per Share** | $-1.30 | $-1.53 | $-0.88 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.